Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

A. Faggiano, F. Grimaldi, L. Pezzullo, M. G. Chiofalo, C. Caracò, N. Mozillo, G. Angeletti, F. Santeusanio, G. Lombardi, A. Colao, N. Avenia, P. Ferolla

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In patients with postoperative persistent medullary thyroid cancer (MTC), the tumor detection rate is generally low for most of the imaging techniques now available. The aim of this study was to investigate if the clinico-biological profile of the tumor may indicate which imaging technique to perform in order to identify postoperative persistent or relapsing MTC foci. Thirty-five consecutive MTC patients with detectable and progressively increasing postoperative serum concentrations of calcitonin were enrolled in the study. The detection rates of 18F-deoxy-D-glucose (FDG)-positron emission tomography (PET), somatostatin receptor scintigraphy (SRS), and 131I-metaiodobenzylguanidine scintigraphy (MIBG) were compared in relation with calcitonin and carcinoembryonic antigen serum concentrations, Ki-67 score and results of conventional imaging techniques (CIT). FDG-PET positivity was significantly associated with calcitonin serum concentrations >400 pg/ml and Ki-67 score >2.0% (P800 pg/ml (P2.0% suggests to perform a FDG-PET in addition to conventional imaging. Calcitonin secretion predicts both FDG-PET and SRS uptake but SRS positivity is generally found only in patients with well defined MTC lesions that are also detectable at the conventional imaging examination. MIBG outcome is not predicted by any clinico-biological factors here investigated.

Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalEndocrine-Related Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Radionuclide Imaging
Calcitonin
Positron-Emission Tomography
Somatostatin Receptors
Neoplasms
Serum
Carcinoembryonic Antigen
Biological Factors
Medullary Thyroid cancer
Glucose

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. / Faggiano, A.; Grimaldi, F.; Pezzullo, L.; Chiofalo, M. G.; Caracò, C.; Mozillo, N.; Angeletti, G.; Santeusanio, F.; Lombardi, G.; Colao, A.; Avenia, N.; Ferolla, P.

In: Endocrine-Related Cancer, Vol. 16, No. 1, 2009, p. 225-231.

Research output: Contribution to journalArticle

Faggiano, A. ; Grimaldi, F. ; Pezzullo, L. ; Chiofalo, M. G. ; Caracò, C. ; Mozillo, N. ; Angeletti, G. ; Santeusanio, F. ; Lombardi, G. ; Colao, A. ; Avenia, N. ; Ferolla, P. / Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. In: Endocrine-Related Cancer. 2009 ; Vol. 16, No. 1. pp. 225-231.
@article{6a207f366f0e4f5c839e150625d6a458,
title = "Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer",
abstract = "In patients with postoperative persistent medullary thyroid cancer (MTC), the tumor detection rate is generally low for most of the imaging techniques now available. The aim of this study was to investigate if the clinico-biological profile of the tumor may indicate which imaging technique to perform in order to identify postoperative persistent or relapsing MTC foci. Thirty-five consecutive MTC patients with detectable and progressively increasing postoperative serum concentrations of calcitonin were enrolled in the study. The detection rates of 18F-deoxy-D-glucose (FDG)-positron emission tomography (PET), somatostatin receptor scintigraphy (SRS), and 131I-metaiodobenzylguanidine scintigraphy (MIBG) were compared in relation with calcitonin and carcinoembryonic antigen serum concentrations, Ki-67 score and results of conventional imaging techniques (CIT). FDG-PET positivity was significantly associated with calcitonin serum concentrations >400 pg/ml and Ki-67 score >2.0{\%} (P800 pg/ml (P2.0{\%} suggests to perform a FDG-PET in addition to conventional imaging. Calcitonin secretion predicts both FDG-PET and SRS uptake but SRS positivity is generally found only in patients with well defined MTC lesions that are also detectable at the conventional imaging examination. MIBG outcome is not predicted by any clinico-biological factors here investigated.",
author = "A. Faggiano and F. Grimaldi and L. Pezzullo and Chiofalo, {M. G.} and C. Carac{\`o} and N. Mozillo and G. Angeletti and F. Santeusanio and G. Lombardi and A. Colao and N. Avenia and P. Ferolla",
year = "2009",
doi = "10.1677/ERC-08-0152",
language = "English",
volume = "16",
pages = "225--231",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

AU - Faggiano, A.

AU - Grimaldi, F.

AU - Pezzullo, L.

AU - Chiofalo, M. G.

AU - Caracò, C.

AU - Mozillo, N.

AU - Angeletti, G.

AU - Santeusanio, F.

AU - Lombardi, G.

AU - Colao, A.

AU - Avenia, N.

AU - Ferolla, P.

PY - 2009

Y1 - 2009

N2 - In patients with postoperative persistent medullary thyroid cancer (MTC), the tumor detection rate is generally low for most of the imaging techniques now available. The aim of this study was to investigate if the clinico-biological profile of the tumor may indicate which imaging technique to perform in order to identify postoperative persistent or relapsing MTC foci. Thirty-five consecutive MTC patients with detectable and progressively increasing postoperative serum concentrations of calcitonin were enrolled in the study. The detection rates of 18F-deoxy-D-glucose (FDG)-positron emission tomography (PET), somatostatin receptor scintigraphy (SRS), and 131I-metaiodobenzylguanidine scintigraphy (MIBG) were compared in relation with calcitonin and carcinoembryonic antigen serum concentrations, Ki-67 score and results of conventional imaging techniques (CIT). FDG-PET positivity was significantly associated with calcitonin serum concentrations >400 pg/ml and Ki-67 score >2.0% (P800 pg/ml (P2.0% suggests to perform a FDG-PET in addition to conventional imaging. Calcitonin secretion predicts both FDG-PET and SRS uptake but SRS positivity is generally found only in patients with well defined MTC lesions that are also detectable at the conventional imaging examination. MIBG outcome is not predicted by any clinico-biological factors here investigated.

AB - In patients with postoperative persistent medullary thyroid cancer (MTC), the tumor detection rate is generally low for most of the imaging techniques now available. The aim of this study was to investigate if the clinico-biological profile of the tumor may indicate which imaging technique to perform in order to identify postoperative persistent or relapsing MTC foci. Thirty-five consecutive MTC patients with detectable and progressively increasing postoperative serum concentrations of calcitonin were enrolled in the study. The detection rates of 18F-deoxy-D-glucose (FDG)-positron emission tomography (PET), somatostatin receptor scintigraphy (SRS), and 131I-metaiodobenzylguanidine scintigraphy (MIBG) were compared in relation with calcitonin and carcinoembryonic antigen serum concentrations, Ki-67 score and results of conventional imaging techniques (CIT). FDG-PET positivity was significantly associated with calcitonin serum concentrations >400 pg/ml and Ki-67 score >2.0% (P800 pg/ml (P2.0% suggests to perform a FDG-PET in addition to conventional imaging. Calcitonin secretion predicts both FDG-PET and SRS uptake but SRS positivity is generally found only in patients with well defined MTC lesions that are also detectable at the conventional imaging examination. MIBG outcome is not predicted by any clinico-biological factors here investigated.

UR - http://www.scopus.com/inward/record.url?scp=65549130102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549130102&partnerID=8YFLogxK

U2 - 10.1677/ERC-08-0152

DO - 10.1677/ERC-08-0152

M3 - Article

C2 - 19004986

AN - SCOPUS:65549130102

VL - 16

SP - 225

EP - 231

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 1

ER -